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Abstract
Background: In healthy individuals, Cytomegalovirus (CMV) infection is efficiently controlled by CMV-specific cell-
mediated immunity (CMI). Functional impairment of CMI in immunocompromized individuals however can lead to
uncontrolled CMV replication and severe clinical complications. Close monitoring of CMV-specific CMI is therefore
clinically relevant and might allow a reliable prognosis of CMV disease as well as assist personalized therapeutic
decisions.
Methods: Objective of this work was the optimization and technical validation of an IFN-γ ELISpot assay for a
standardized, sensitive and reliable quantification of CMV-reactive effector cells. T-activated® immunodominant CMV
IE-1 and pp65 proteins were used as stimulants. All basic assay parameters and reagents were tested and optimized
to establish a user-friendly protocol and maximize the signal-to-noise ratio of the ELISpot assay.
Results: Optimized and standardized ELISpot revealed low intra-assay, inter-assay and inter-operator variability
(coefficient of variation CV below 22%) and CV inter-site was lower than 40%. Good assay linearity was obtained between
6 × 104 and 2 × 105 PBMC per well upon stimulation with T-activated® IE-1 (R2 = 0.97) and pp65 (R2 = 0.99) antigens.
Remarkably, stimulation of peripheral blood mononuclear cells (PBMC) with T-activated® IE-1 and pp65 proteins resulted
in the activation of a broad range of CMV-reactive effector cells, including CD3+CD4+ (Th), CD3+CD8+ (CTL), CD3−CD56+
(NK) and CD3+CD56+ (NKT-like) cells. Accordingly, the optimized IFN-γ ELISpot assay revealed very high sensitivity (97%) in
a cohort of 45 healthy donors, of which 32 were CMV IgG-seropositive.
Conclusion: The combined use of T-activated® IE-1 and pp65 proteins for the stimulation of PBMC with the optimized
IFN-γ ELISpot assay represents a highly standardized, valuable tool to monitor the functionality of CMV-specific CMI with
great sensitivity and reliability.
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Background
Human cytomegalovirus (CMV) is endemic in all human
populations, with a seroprevalence ranging from 36 to
100% depending on age, gender and location [1]. In
healthy individuals, CMV replication is efficiently con-
trolled by cell-mediated immunity (CMI). In immuno-
compromized individuals however, the reduced frequency
and functionality of CMV-reactive effector cells is associ-
ated with severe clinical complications due to uncon-
trolled virus replication [1–3]. Quantitative assessment of
functional CMV-reactive effector cells in immunocompro-
mized individuals might help to identify patients at in-
creased risk for CMV-mediated clinical complications and
to adjust antiviral and immunosuppressive therapy [3, 4].
Reliable monitoring of CMV-specific CMI in immu-
nocompromized individuals, such as solid-organ or
allogeneic stem cell transplant recipients, requires a
specific, standardized but also highly sensitive assay
capable of detecting low numbers of CMV-reactive
cells. Such sensitivity might be achieved by using
highly immunogenic stimulants and via the reactiva-
tion of a broad spectrum of physiological effector
cells involved in the protection against CMV replica-
tion in vivo, notably CD4+ (T helper or Th), CD8+
(cytotoxic T lymphocytes or CTL), but also natural
killer (NK) and natural killer T (NKT) cells [5–12].
Current diagnostic methods to detect and monitor
CMV-specific CMI are mostly based on the restimula-
tion of CD4+ and/or CD8+ effector cells with pools of
overlapping peptides, cocktails of preselected immuno-
dominant CMV-peptides or lysates of CMV-infected
cells and the subsequent measurement of induced cyto-
kine production (e.g. IFN-γ) or cell proliferation, by flow
cytometry, enzyme-linked immunosorbent assay (ELISA)
or enzyme-linked immunospot assay (ELISpot). A dif-
ferent approach consists in the direct staining with
CMV-peptide-loaded multimers and enumeration of
CMV-specific CD8+ T cells by flow cytometry. How-
ever, this method is lacking a functional readout and
is restricted to certain HLA types, impeding its use in
routine diagnostics.
ELISA-based assays, such as QuantiFERON®-CMV are
advantageous in that they require low blood volumes
and are easy to perform [13]. However, they are re-
stricted to the detection of IFN-γ-producing CD8+ T
cells and do not allow single-cell-level measurement.
Due to analyte dilution, ELISA-based assays usually re-
sult in reduced sensitivity [14, 15] and often yield inde-
terminate results, especially in immunocompromized
patients [16–21]. Intracellular cytokine staining (ICS)
and subsequent flow cytometric analysis is usually more
sensitive than ELISA [15, 20] and allows the assessment
of both the functionality and the phenotype of
CMV-reactivated cytokine-producing cells. However, this
method is difficult to standardize and only detects the
intracellular analyte, not the biologically active cytokine
secreted over the stimulation period.
ELISpot-based assays identify and enumerate biologic-
ally active, cytokine-secreting cells from isolated periph-
eral blood mononuclear cells (PBMC), at the single-cell
level both qualitatively and quantitatively [22]. ELISpot
represents the most sensitive read-out system and thus
is most appropriate for the detection of low-level re-
sponses [23, 24]. In particular, ELISpot is more sensitive
than ICS for the detection of antigen-specific cells, such
as in vitro-reactivated memory T cells, which produce
only low amounts of cytokines [15, 25]. ELISpot was
recently successfully employed over ELISA in the detec-
tion of congenital CMV infection [26–28].
Conventional CMV-specific ELISpot assays are based
on the detection of IFN-γ-producing CD4+ and/or CD8+
T cells, depending on the antigens used for PBMC
stimulation [23, 24, 29, 30]. The careful selection and
formulation of antigens is crucial to ensure specificity,
sensitivity and thus a diagnostic value to the assay. We
have previously shown that urea-formulated recombin-
ant (T-activated®) proteins are processed by the exogen-
ous and endogenous antigen processing machinery,
resulting in the presentation of naturally generated
peptides by MHC class II and class I molecules [31].
Stimulation of PBMC by T-activated® proteins thus
mimics more closely a natural infection, resulting not
only in the specific activation of memory T (CD4+,
CD8+) and NK cells, but also possibly in the by-
stander activation of NK and NKT-like cells present
in the PBMC population [31, 32].
We describe here the establishment, optimization and
standardization of a highly sensitive ELISpot assay that
takes advantage of both the IFN-γ ELISpot readout and
the immunodominant and highly immunogenic T-
activated® IE-1 and pp65 CMV proteins as stimulants.
We also compared the performance of the optimized
assay to that of intracellular staining and flow cytometry
in healthy CMV-seropositive donors, and demonstrated
the ability of T-activated® IE-1 and pp65 antigens to acti-
vate a broad spectrum of CMV-reactive cells, including
CD3+CD4+ (Th), CD3+CD8+ (CTL), CD3−CD56+ (NK)
and CD3+CD56+ (NKT-like) cells. Therefore, the com-
bined use of T-activated® IE-1 and pp65 CMV proteins
with our optimized IFN-γ ELISpot defines a highly
sensitive assay meeting all conditions for a reliable and
standardized immune monitoring diagnostic tool.
Methods
Proteins, ELISpot plate precoating and detection conjugate
Urea-formulated T-activated® proteins were prepared as
previously described [31]. The T-activated® immunodo-
minant region of CMV pp65 (amino acids 366 to 546,
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hCMV strain AD169 [33]) was provided by MIKROGEN
(MIKROGEN GmbH, Neuried, Germany). Full length
IE-1 (hCMV towne strain) was kindly provided by
Christina Paulus and Michael Nevels (University of
Regensburg, Germany). T-activation® of IE-1 was per-
formed by Lophius Biosciences. Staphylococcal entero-
toxin B (SEB; 11249738001, Roche Diagnostics GmbH,
Mannheim, Germany) and phytohemagglutinin (PHA;
S4881, Sigma-Aldrich Chemie GmbH, Munich, Germany)
were used as positive controls for PBMC stimulation. 96-
well ELISpot plates (MAIPS4510, Merck Millipore, Merck
KGaA, Darmstadt, Germany) and 8-well ELISpot strips
(M8IPS4510, Merck Millipore) each pre-coated with anti-
human-IFN-γ mAb 1-D1K (MabTech, Nacka Strand,
Sweden) as well as the detection conjugate mAb-AP
(7-B6-1) (MabTech, Nacka Strand, Sweden) coupled with
alkaline phosphatase (Roche, Basel, Switzerland) were
obtained from Microcoat Biotechnologie GmbH.
Blood collection and PBMC preparation
Blood samples were collected in lithium heparin tubes
(S-Monovette®, Sarstedt, SARSTEDT AG & Co.,
Nümbrecht, Germany) from healthy individuals with
known CMV serostatus by venipuncture and stored for
up to 8 hours at room temperature (18-25 °C) until fur-
ther processing. Isolation of peripheral blood mono-
nuclear cells (PBMC) was performed using standard
Ficoll-Paque density centrifugation as specified by the
manufacturer (Pancoll human, PAN-Biotech GmbH,
Aidenbach, Germany). PBMC were finally suspended in
serum-free AIM-V® medium (Life Technologies, Inc.,
Grand Island, NY) and counted either manually in a
Neubauer’s chamber or using the Hem-o-test 2000 cell-
counting device (BGT BioGenTechnologies GmbH,
Steinfurt, Germany). Automated cell counting was per-
formed in the whole blood venous mode of the cali-
brated analyzer.
ELISpot assay
IFN-γ ELISpot assays were performed as previously de-
scribed [31] unless specified otherwise in the Results
section. Briefly, 2 × 105 freshly isolated PBMC were
plated in four replicates into 96-well ELISpot plates or
8-well ELISpot strips precoated with anti-human-IFN-γ
mAb 1-D1K (Microcoat Biotechnologie GmbH) and
stimulated for 19 h at 37 °C under 5% CO2 with either
3 μg/ml T-activated® pp65 antigen or 15 μg/ml T-acti-
vated® IE-1 protein. As unstimulated control (neg.), cells
were incubated for 19 h in cell culture medium. After
cell removal, plates were developed for 2 h at room
temperature (18-25 °C) in the presence of 0.4 U/ml IFN-
γ-specific alkaline phosphatase-coupled mAb 7-B6-1.
Spot detection was performed following incubation
for 6 min in the dark with a 1-step nitroblue
tetrazolium–5-bromo-4-chloro-3-indolylphosphate sub-
strate (Thermo Fischer Scientific, Waltham, USA). IFN-γ-
specific spot-forming cells (SFC) were counted using a
Bioreader® 5000 Eα (BIO-SYS GmbH, Karben, Germany).
Of note, comparable results were obtained on two other
readers (AID Elispot Robotic System ELROB05i and CTL
ImmunoSpot® S6).
Intracellular cytokine staining
Intracellular cytokine staining was performed as previ-
ously described [31], with the following modifications.
PBMC from six healthy CMV-seropositive donors were
isolated and four replicates each were stimulated for 6 h
at 37 °C and 5% CO2 with 3 μg/ml T-activated® pp65
antigen or with 15 μg/ml T-activated® IE-1 protein in the
presence of co-stimulatory anti-CD28 and anti-CD49d
monoclonal antibodies (BD, Heidelberg, Germany). The
unstimulated PBMC control cells were incubated with
co-stimulatory anti-CD28 and anti-CD49d molecules
only. Stimulation with SEB and anti-CD28 + anti-CD49d
served as positive control. After the first two hours of
incubation, 1 μg/ml brefeldin A (BFA, Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) was added to pre-
vent cytokine secretion from activated cells. Surface
markers (CD3, CD4, CD8, CD56) were stained for
30 min at 4 °C using the following conjugated antibodies
(all from Biolegend, London, UK): anti-CD3 APC-Cy7,
anti-CD4 Brilliant Violet 421, anti-CD8 FITC, anti-
CD56 PerCP. Cells were fixed and permeabilized for
30 min at 4 °C in BD Cytofix/Cytoperm (BD, Heidelberg,
Germany). Intracellular staining of IFN-γ was performed
using anti-IFN-γ APC (Biolegend, London, UK) in BD
Perm/Wash Buffer (BD, Heidelberg, Germany) for
45 min at 4 °C. Samples were analyzed on a BD FACS-
Canto™ II flow cytometer (Becton Dickinson, USA).
Live-gating of cells was performed during acquisition.
Mean (SD) number of event acquisition was 172,904
(108,298). Results were reported as percentage of the
gated population producing IFN-γ (dot plots) and as
the number of IFN-γ+ cells/200,000 lymphocytes (bar
graphs).
Serology
The CMV serological testing of blood donors was per-
formed using the fully automated CMV immunoglobulin
M (IgM) and IgG tests on the Architect instrument
(Abbott Laboratories, Abbott Park, IL) or the BEP® III
system (Siemens Healthcare) by the diagnostics depart-
ment of the Institute for Medical Microbiology and
Hygiene (University of Regensburg, Germany). CMV
IgG-serology was used as primary reference measure-
ment procedure (gold standard method).
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Statistics
Statistics applied to assay development was performed
using SigmaPlot Version 11.0 and GraphPad Prism 5.04.
At the start of this study, a positive ELISpot test result
was defined by a statistically significant difference be-
tween quadruplicate SFC values of non-stimulated and
specifically stimulated approaches of at least one of the
two antigens used, calculated using the Mann–Whitney
U-Test (MWU) (SigmaPlot). Two-sided exact P values
are reported. P values < 0.05 were considered statistically
significant. Statistical analyses to assess variations be-
tween two or more settings were performed by generat-
ing arithmetic means for all replicates of each given
setting. Those means were grouped to generate an over-
all arithmetic mean and standard deviation. The coeffi-
cient of variation in % (ratio of the standard deviation to
the mean multiplied by 100) was calculated in Microsoft
Excel. The curve fitting for sigmoidal curves of the titra-
tion experiment (Fig. 1) was performed using the four
parameter logistic function of GraphPad Prism 5.04. For
the assessment of the ELISpot assay sensitivity in sero-
positive healthy blood donor collectives, the non-
parametric Mann–Whitney U-Test (MWU test) was
performed to determine if a significant difference exists
between the groups of negative control and stimulation
quadruplicates. Multiple-group comparisons were per-
formed using a non-parametric One-way ANOVA
(Kruskal-Wallis test) with Dunn’s multiple comparison
post test. SFC values were depicted using GraphPad
Prism 5.04 either as Tukey box plots showing median
values (horizontal line), interquartile ranges (IQR: Q3-Q1),
lower and upper whiskers (Q1-1.5xIQR and Q3 + 1.5xIQR
respectively) and outliers (below Q1-1.5xIQR and above
Q3 + 1.5xIQR; black dots), or as histograms. For assay val-
idation of optimized ELISpot, positivity cut-off was calcu-
lated on IFN-γ ELISpot results obtained from a collective
of 45 healthy donors using SAS 9.2 Software and VFP
(Variance Function Program; option “Simple variance func-
tion estimate”) version 12.0.
Results
IFN-γ ELISpot assay optimization following PBMC
stimulation with T-activated® IE-1 and pp65 CMV antigens
Freshly isolated PBMC were used for the ELISpot assay.
To prevent loss in T cell functionality, for instance due
to activated granulocytes [34], heparinized blood sam-
ples were processed with no further additives within 8 h.
A total number of 2 × 105 PBMC per well was chosen
for the development of the ELISpot assay protocol as
this cell count is below confluency and can usually be
obtained from samples of less than 15 ml whole blood.
The CMV immediate-early protein IE-1 and the late
tegument protein pp65 represent well-characterized
immunodominant T cell antigens [1, 24, 35]. Full-length
IE-1 and a 181 amino-acid C-terminal fragment of pp65
were produced and formulated in the presence of urea
(T-activation®) to increase their stimulatory capacity for
different types of CMV-reactive effector cells of cell-
mediated immunity [31]. Optimal T-activated® antigen
concentration was first determined by performing dose–
response experiments. Freshly isolated PBMC of one
healthy CMV-seropositive donor were stimulated with
31.6 fg/ml to 31.6 μg/ml T-activated® pp65 or with 0.01
to 31.6 μg/ml T-activated® IE-1, and the number of IFN-
γ secreting cells was determined by IFN-γ ELISpot.
T-activated® pp65 revealed a much stronger capacity to
stimulate IFN-γ secreting effector cells than T-activated®
IE-1, reaching a plateau of responsiveness between
0.316 and 3.16 ng/ml pp65 vs. approximately 31.6 μg/
ml for IE-1 (Fig. 1). Accordingly, T-activated® antigen
concentrations of 3 μg/ml pp65 and 15 μg/ml IE-1
were selected for further PBMC stimulations and ELI-
Spot assays.
Assay sensitivity and specificity were determined by
stimulating PBMC isolated from 10 each CMV-
seropositive and CMV-seronegative healthy donors with
the defined pp65 and IE-1 T-activated® antigen concen-
trations. The number of reactive effector cells was quan-
tified by IFN-γ ELISpot. Significant stimulation was
defined using a Mann–Whitney U-Test as a statistically
significant difference between SFC values of non-
stimulated and CMV antigen-stimulated conditions
(each in quadruplicate). T-activated® pp65 and IE-1 in-
duced a significant activation of responsive effector cells
in 10 out of 10 and 9 out of 10 PBMC preparations from
individual CMV-seropositive donors, respectively (Fig. 2).
Fig. 1 Determination of optimal concentrations of T-activated® pp65
and IE-1 for the stimulation of PBMC. PBMC were isolated from one
CMV-seropositive healthy donor blood sample and stimulated for 19 h
with increasing concentrations of T-activated® pp65 (31.6 fg/ml-31.6 μg/
ml; black circles) or IE-1 (0.01-31.6 μg/ml; black squares). IFN-γ ELISpot
results of four replicates are expressed as mean SFC/200,000 PBMC. Error
bars represent standard deviations. The Y-axis scale was adjusted to
pp65- (left) and IE-1- (right) specific values to optimize data resolution.
Curve fitting was made using the four parameter logistic function of
GraphPad Prism 5.04
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In this collective, T-activated® pp65 showed an overall
greater capacity to activate responsive cells with a me-
dian of 399 SFC/200,000 PBMC (range 12–864 SFC/
200,000 PBMC), compared to T-activated® IE-1 with a
median of 26 SFC/200,000 PBMC (range 1.3-96 SFC/
200,000 PBMC). Nevertheless, substantial response of
up to 96 SFC/200,000 PBMC was detected in response
to T-activated® IE-1 in individual samples of CMV-
seropositive donors (Fig. 2). All 10 PBMC samples
(100%) from different CMV-seronegative donors showed
negative test results after stimulation with pp65 (median
0.3 SFC/200,000 PBMC; range 0–2.8), while 9 out of 10
(90%) PBMC samples from CMV-seronegative individ-
uals were negative after stimulation with IE-1 (median
2.9 SFC/200,000 PBMC; range 0.3-6.8). Spot count
within CMV-seronegative IE-1-stimulated PBMC was
higher than in CMV-seronegative pp65-stimulated
PBMC but did not exceed 7 SFC/200,000 PBMC (Fig. 2).
IFN-γ has been shown to be secreted continuously
during antigen stimulation. Thus, signal intensity in
IFN-γ ELISpot is dependent on the duration of stimula-
tion [14, 36]. The duration of antigen stimulation in
IFN-γ ELISpot reported in the literature usually ranges
from 16 to 24 h [37–42]. To address the influence of the
incubation time on the test results, IFN-γ ELISpot were
performed on PBMC from 3 independent CMV-
seropositive healthy donors following stimulation with
T-activated® pp65 and IE-1 antigens for 17, 19 and 21 h.
No statistically significant differences in SFC numbers
were detected between the 3 conditions (Fig. 3), demon-
strating signal stability in this time range. Thus, an
incubation time of 19 h was chosen for the optimized
ELISpot assay.
Numerous protocol variables can affect ELISpot test
results. For instance, the medium used for primary cell
culture often includes serum which contains various
batch-dependent non-characterized bioactive molecules
in different concentrations [43]. In order to define stan-
dardized cell culture conditions, the impact on the assay
performance of different serum-containing media (RPMI
1640 supplemented with 5% of either FCS, human AB,
synthetic NTA or synthetic NTS) and of serum-free
media (AIM-V®, UltraCulture) was investigated. Serum-
free media yielded the best effector cell responses, com-
parable to that of RPMI 1640 supplemented with 5%
FCS (Fig. 4a). In addition, AIM-V® exhibited lowest
background signals in unstimulated conditions (Fig. 4b),
thus maximizing signal-to-noise ratio. Consequently, the
ELISpot protocol was further established using AIM-V®
serum-free medium.
ELISpot assays can be performed with various mem-
brane materials, including nitrocellulose (NC), mixed
cellulose ester (MCE) and polyvinylidene fluoride
(PVDF). We compared IFN-γ ELISpot results from
PBMC samples of six healthy individuals (four replicates
each, two preparations per donor) employing the most
commonly used MCE plates, PVDF plates and PVDF
strips from Millipore (Merck Millipore, Merck KGaA,
Darmstadt, Germany). PVDF membranes require an ac-
tivation step with ethanol prior to binding of the capture
antibody. In addition, more stringent washing steps prior
to spot development were needed using PVDF-based
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Fig. 2 Determination of assay sensitivity and specificity. PBMC from 10 each CMV-seropositive and CMV-negative healthy blood donors were left
unstimulated (neg.) or were stimulated with T-activated® pp65 or IE-1 and IFN-γ ELISpot assays were conducted as before. Mean SFC values per
200,000 PBMC of 4 replicates are shown as box plots. Median values (horizontal black lines) are indicated in brackets. Y-axis scales were adjusted in
each graph for better resolution of SFC counts. Median age and range of CMV-seronegative and CMV-seropositive subjects was 28 (24–53) and
31 (23–56) years. Gender distribution in CMV-seronegative (30% male and 70% female) and CMV-seropositive (25% male and 75% female)
groups was comparable. Differences between unstimulated and stimulated conditions were tested using the non-parametric two-sided Mann–Whitney U
(MWU) test. P-values < 0.05 were considered statistically significant
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plates compared to MCE plates, to avoid undesirable
background staining of membranes. Nevertheless, the
resolution of the detected spots in terms of sharpness
and homogeneity was improved on PVDF membranes
(not shown), resulting in higher spot counts compared
to MCE membranes (up to 10-times more in the case of
IE-1 stimulations, with a median SFC of 155 vs. 13/
200,000 PBMC, respectively; Fig. 5). Since PVDF 8-well
strips were more performant and because their use
might allow reduced costs, in particular when single
patient samples are tested in clinical routine, the PVDF
8-well-strip format was chosen for the optimized assay
development.
Optimal coating of microtiter plates with capture anti-
body is crucial for a robust assay performance. The
density of IFN-γ capture antibody bound to the PVDF
membrane should not be limiting and, in particular,
should allow the reliable detection of high spot counts.
PVDF strips were coated with increasing concentrations
(2.5 to 7.5 μg/ml) of anti-IFN-γ antibody. PBMC from
five CMV-seropositive donors were seeded into the
coated wells and either left unstimulated or stimulated
with T-activated® IE-1 or pp65. In the range of 2.5 to
7.5 μg/ml, increasing antibody concentrations had no
effect on background staining in unstimulated PBMC
(median SFC of 0 to 0.5/200,000 PBMC regardless of
IFN-γ capture antibody concentration; Figs. 6a-b). Simi-
larly, IE-1-specific low-to-moderate SFC levels (medians
of 19 to 26 SFC/200,000 PBMC) were comparable in all
coating-antibody conditions (Fig. 6a). The same was
true for pp65-specific responses up to ~300 SFC/
200,000 PBMC (donors d032, d120 and d241; Fig. 6c).
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Fig. 3 Effect of duration of antigen stimulation on IFN-γ ELISpot test results. SFC counts (means of four replicates) in IFN-γ ELISpot following
stimulation of PBMC samples from three CMV-seropositive healthy donors (d120, 32-year-old male; d254, 62-year-old female; d270, 22-year-old female) with
T-activated® IE-1 or pp65 for 17, 19 and 21 h. Unstimulated PBMC (neg.) were used as a negative control. Differences between stimulation durations were
tested using the non-parametric two-sided One-way ANOVA Kruskal-Wallis test (*P< 0.05). P-values < 0.05 were considered statistically significant
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Fig. 4 Evaluation of different cell culture media on the performance of IFN-γ ELISpot. a Boxplot diagram showing ELISpot results upon stimulation
of PBMC of 10 CMV-seropositive healthy blood donors (median age and range of 31 (26–54) years; 40% male and 60% female) with T-activated®
pp65 in various cell culture media. Median values (horizontal black lines) are indicated in brackets. Differences between medium conditions among
stimulated conditions were tested using the non-parametric two-sided One-way ANOVA Kruskal-Wallis test (p = 0.613). b ELISpot results of the non-
stimulated cells incubated in AIM-V or in UltraCulture (UC) serum-free media are shown separately with an expanded Y-axis scale. Differences between
both conditions were tested using the non-parametric two-sided MWU test (p = 0.074). P-values < 0.05 were considered statistically significant.
Serum-containing media were composed of RPMI 1640 supplemented with 5% serum (R5): FCS, NTA, NTS or human AB (hAB)
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In contrast, in individual donors with higher spot
counts (e.g., d172, d202; Fig. 6c), detection of pp65-
reactive cells increased in a dose-dependent manner
with the concentration of IFN-γ capture antibody
used for coating, especially between 2.5 and 5 μg/ml
antibody. At antibody concentrations of 5 μg/ml and
beyond, spot counts remained stable (Figs. 6b-c).
Based on these results, a concentration of 5 μg/ml
IFN-γ capture antibody was chosen for coating in the
optimized ELISpot protocol.
ELISpot assays rely on the detection of captured cyto-
kine by cytokine-specific antibodies, which can be either
directly coupled to a reporter enzyme (one-step assay
development), like alkaline phosphatase (AP), or a com-
bination of a biotinylated secondary antibody and a
streptavidin-conjugated reporter enzyme (two-step assay
development). A one-step assay development saves
handling time and prevents operator errors. AP-
conjugated mAb (7-B6-1) (MicroCoat Biotechnologie
GmbH, Bernried, Germany) was used as detection con-
jugate for the standardized ELISpot protocol. Different
incubation parameters (e.g., 0.5 – 3 h at 37 °C, 2 h at
room temperature [RT, 18-25 °C]) were tested. Spot
counts were comparable in all conditions. However, spot
S
F
C
 /
 2
00
,0
00
 P
B
M
C
MCE PVDF strips MCE PVDF strips MCE PVDF strips 
0
200
400
600
800
1000
neg. IE-1 pp65
(4.0)(0.5) (13)(8.1)
(155)
(100)
(424)
(374)
(446)
p<0.001 p<0.001 p=0.375
Fig. 5 Comparison of IFN-γ ELISpot performance using different
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morphology and thus proper detection was best upon
incubation with AP-conjugate for 2 h at RT, compared
to other conditions (not shown). Increase in the concen-
tration of the detection conjugate from 0.025 to 0.4 U/
ml resulted in slightly elevated SFC median values for
pp65, and the maximum spot counts exceeded those
generated by the two-step assay development (not
shown). Therefore, a one-step assay development for 2 h
at RT with 0.4 U/ml detection conjugate was chosen.
Finally, standardization of the SFC staining reaction
was addressed to complete assay optimization. Duration
of incubation with the AP substrate affects spot size
and/or background level, and is thus critical for reliable
spot enumeration. A one-step chromogenic alkaline
phosphatase substrate NBT/BCIP (Thermo Fischer
Scientific, Waltham, USA) was used as staining solution,
and incubation times ranging from 2 to 13 min in the
dark were evaluated. SFC counts were comparable in all
conditions. However, shorter incubation times resulted
in smaller spot diameter, while longer incubation times
yielded enhanced background levels (data not shown).
Therefore, a staining duration of six minutes in the dark
was defined for the optimized ELISpot protocol.
Linearity and precision of the optimized CMV ELISpot assay
The optimized ELISpot protocol was used to determine
the working range of PBMC that ensure assay linearity.
PBMC from one healthy CMV-seropositive donor were
seeded at a density ranging from 2 × 104 to 2.5 × 105
PBMC per well. For cell numbers between 6 × 104 and 2
× 105 PBMC per well, ELISpot counts were directly
proportional to the number of PBMC seeded, follow-
ing stimulation with either IE-1 (linear regression
analysis; R2 = 0.97) or pp65 (R2 = 0.99) (Fig. 7a).
Because of the usually lower spot count resulting
from IE-1 stimulation, the use of 2 × 105 PBMC per
well was chosen for the standardized ELISpot assay,
to ensure sufficient SFC values.
To further verify the linearity between the number of
CMV-reactive effector cells and enumerated SFC, in-
creasing numbers of PBMC from one CMV-seropositive
healthy donor were seeded and the total number of
PBMC was adjusted to 2 x 105 per well using PBMC
from one CMV-seronegative donor. Two donor pairs
(d034 + d219, d204 + d067) that showed no allo-
reactivity in a 19-h co-culture were chosen for these ex-
periments. Due to low SFC numbers (below 20 SFC/
200,000 PBMC), IE-1 stimulation results showed in-
creased variability compared to pp65 and did not allow a
reliable linearity calculation (R2 values below 0.96; data
not shown). ELISpot assay results following pp65 stimu-
lation showed a good linear correlation for both donor
pairs, with R2 values of 0.99 (d034 + d219) and 0.98
(d204 + d067) in the linear regression analysis (Fig. 7b).
Precision and repeatability of the optimized assay were
evaluated by calculating the intra-assay, inter-assay,
inter-operator and inter-site variability. In each case,
PBMC from three CMV-seropositive healthy donors
were tested in quadruplicate, and variability was assessed
by calculating the coefficient of variation (CV), defined
as the ratio of the standard deviation to the mean. CV
for ELISpot values < 10 SFC/200,000 PBMC were not
calculated (see positivity cut-off calculation below). CV
intra-assay reached 14% for IE-1 stimulation and 6% for
pp65 stimulation (Additional File 1: Table S1). CV inter-
assay did not exceed 17% for IE-1 and 22% for pp65
(Additional File 1: Table S2). CV inter-operator was
below 13% and 18% for IE-1 and pp65 respectively
(Additional File 1: Table S3). Finally, inter-site variation,
which is essential for assay validation for diagnostics
Fig. 7 IFN-γ ELISpot assay linearity. a Working range of PBMC per ELISpot assay. Increasing number of PBMC from one CMV-seropositive healthy
donor were seeded per well and ELISpot assays were performed as described, following stimulation with T-activated® IE-1 or pp65. Mean SFC
values and standard deviation obtained for 60,000-200,000 PBMC per well are depicted. Scale of the Y-axes was adjusted for pp65 (left) and IE-1
(right) for a better data resolution. b Linearity between the number of CMV-reactive PBMC and enumerated SFC. The indicated numbers of PBMC
from one CMV-seropositive healthy donor were mixed with PBMC from one CMV-seronegative donor (up to 200,000 total PBMC) and stimulated
with T-activated® pp65 antigen according to the optimized protocol. Mean SFC values and standard deviation of quadruplicate measurements are
shown for two donor pairs (d034 + d219, d204 + d067). In both panels, regression lines and corresponding coefficient of determination R2 were generated
using the regression line tool of GraphPad Prism 5.04
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purposes, was evaluated. Whole blood samples were
simultaneously collected from three CMV-seropositive
healthy donors and shipped (under constant condition at
RT) to four different laboratories in Germany. PBMC
were freshly isolated and ELISpot assays performed
according to the optimized protocol by a total of 7 oper-
ators. CV inter-site reached a maximum of 39% for IE-1
and of 28% for pp65 (Additional File 1: Table S4).
Evaluation of at least four independent measurements
has been recommended to achieve statistically significant
ELISpot results [44–46]. To address the influence of
intra-replicate variations on the assay outcome, we com-
pared ELISpot results of quintuplicate and quadruplicate
measurements of each control and antigen stimulations.
No significant variation of test results was found (data
not shown). Therefore, quadruplicate measurements of
unstimulated and T-activated® IE-1- and pp65-stimulated
conditions allow assay reliability, as well as practicability
in combination with the use of 8-well strips.
Staphylococcal enterotoxin B (SEB) is a powerful
superantigen, and phytohemagglutinin (PHA) a potent
mitogen, both inducing massive IFN-γ secretion by T
cells [47, 48]. Thus SEB and PHA are suitable positive
controls for cell viability, successful stimulation of cyto-
kine secretion and overall T cell functionality. This is
particularly important for result interpretation when low
T cell frequency is expected, for instance in recipients of
allogeneic stem cell transplantation. In the optimized
ELISpot assay, stimulations of test samples with either
SEB or PHA are performed in duplicate.
In addition, an effector cell-independent operator con-
trol was established to validate proper assay perform-
ance. This operator control is based on the detection of
recombinant IFN-γ upon direct incubation with the
immobilized anti-human-IFN-γ mAb (1-D1K) capture
antibody. This control, also performed in duplicate,
should yield a homogeneous dark staining of the PVDF
membrane.
Technical assay validation: definition of a positivity cut-off
To ease result interpretation of the IFN-γ ELISpot assay
and to maximize specificity (i.e. avoid false positives
within unstimulated conditions and within stimulated
conditions in CMV-seronegative individuals), a technical
cut-off was defined. IFN-γ ELISpot assays were per-
formed according to the optimized protocol on PBMC
from 45 healthy donors, of which 32 were CMV IgG-ser-
opositive (Table 1).
Median and range of SFC values from unstimulated
PBMC of CMV-seronegative and CMV-seropositive in-
dividuals were comparable [median SFC (range) of 0.7
(0.5-8.6) and 0.7 (0.5-2.5)/200,000 PBMC, respectively;
Fig. 8]. Spot counts in IE-1- and pp65-stimulated PBMC
of CMV-seronegative subjects were low [median SFC
(range) of 4.0 (2.0-52) and 1.4 (0.6-7.6)/200,000 PBMC,
respectively; Fig. 8]. In CMV-seropositive individuals,
SFC levels in IE-1- and pp65-stimulated PBMC reached
1114 and 954 spot counts/200,000 PBMC (median of 22
and 265 respectively; Fig. 8). For the determination of a
technical cut-off, spot counts in the unstimulated
control as well as in T-activated® pp65- and IE-1-
stimulated conditions of CMV-seronegative and CMV-
seropositive individuals were taken into consideration.
Positivity threshold was determined using z-statistics
(α-level = 0.05) on log10-transformed geometric mean
Table 1 Technical validation cohort of healthy donors
Median age (range) in years 33 (21; 64)
Gender, N (%)
Male 11 (24.4%)
Female 34 (75.6%)
CMV serostatus, N (%)
Positive 32 (71.1%)
Negative 13 (28.9%)
Fig. 8 Assay validation in immunocompetent donors. PBMC isolated
from whole blood of 45 healthy donors (Table 1) were assayed using the
optimized IFN-γ ELISpot. A positivity cut-off of 10 SFC/200,000 PBMC
(grey horizontal dashed line) was defined (see text and Additional File 2).
Considering a test result as positive when the geometric mean for at
least one of the IE-1 or pp65 stimulated approach is≥ 10 SFC/200,000
PBMC and when the ratio of geometric means of stimulated to
unstimulated conditions is ≥ 2.5, positive agreement (sensitivity)
and negative agreement (specificity) of the optimized IFN-γ ELISpot
test results with CMV serology within this collective of healthy donors
was 97% and 85% respectively
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values. Values = 0 were replaced by values near detec-
tion limit, which was assumed to be 0.5. Standard
deviation (SD) of ELISpot measurements for the un-
stimulated control, IE-1 stimulation and pp65 stimu-
lation was respectively 0.234, 0.192 and 0.136.
Considering a SD of 0.2 and assuming that 4 repli-
cates are measured for each negative control and test
samples, a criterion that the ratio of geometric means
of stimulated to unstimulated values is at least 2.5
was calculated. On the other hand, precision profiles
were generated from both IE-1- and pp65-specific test
results, whereby a coefficient of variation (CV) no
higher than 40% was used as a limit of acceptance of
assay validity to determine the respective limit of
quantitation (LoQ). Precision profiles for IE-1- and
pp65-specific ELISpot results from the 45 healthy do-
nors yielded LoQ values of 8.6 and 7.1 respectively
(Additional File 2). Of note, a similar analysis per-
formed on a cohort of 124 hemodialysis patients pro-
vided comparable SD values within unstimulated and
antigen-stimulated conditions (range 0.199-0.240) and
yielded LoQ values of 7.8 (IE-1) and 8.3 (pp65) [49].
Based on these analyses, a cut-off of 10 SFC/200,000
PBMC was chosen to define positive test results.
Altogether, using T-activated® pp65 and IE-1 antigens
and the optimized IFN-γ ELISpot assay, test results are
considered positive if the geometric mean of the spots
resulting from pp65 or IE1 stimulations are ≥ 10 SFC/
200,000 PBMC and if the ratio of the geometric means
of stimulated to non-stimulated conditions is ≥ 2.5.
According to these definitions, the collective of 45
healthy donors (32 CMV IgG-seropositive, 13 CMV
IgG-seronegative) revealed a sensitivity (defined as the
positive agreement with CMV IgG-serology, used as pri-
mary reference measurement procedure) of 97% and a
specificity (negative agreement with CMV IgG-serology)
of 85% (Fig. 8).
Functional assay validation: T-activated antigens stimulate
a broad spectrum of clinically relevant CMV-reactive
effector cells
Urea-formulated recombinant (T-activated®) proteins are
processed by both the exogenous (MHC class II) and
endogenous (MHC class I) antigen processing and
presentation pathways [31]. Stimulation of PBMC by
T-activated® proteins thus reproduces more closely a
natural infection, potentially resulting in the activation
of a broad spectrum of clinically relevant CMV-reactive
cells (e.g., Th, CTL, NK, NKT cells; [5–12]), which might
contribute to the high sensitivity of the IFN-γ ELISpot
assay. To further characterize the cells targeted by T-ac-
tivated® IE-1 and pp65 antigens and to investigate the
possible inter-individual variability in the effector cells
response, intracellular IFN-γ staining and flow
cytometry analyses were performed in parallel to IFN-γ
ELISpot assays. Freshly isolated PBMC from six CMV-
seropositive healthy donors were stimulated with T-acti-
vated® IE-1 and pp65 proteins for 19 h and IFN-γ-
producing cells enumerated according to the optimized
ELISpot assay. The same PBMC preparations (4 repli-
cates each) were stimulated for 6 h with the same batch
of T-activated® IE-1 and pp65 proteins in the presence of
co-stimulatory anti-CD28 and anti-CD49d antibodies.
Surface markers (CD3, CD4, CD8, CD56) and intracellu-
lar IFN-γ staining were analysed by flow cytometry, as
described in the Methods section. IFN-γ+ subpopulations
of CD3+CD4+ (Th), CD3+CD8+ (CTL), CD3+CD56+
(NKT-like) and CD3−CD56+ (NK) lymphocytes were enu-
merated following the gating strategy illustrated in
Additional File 3. All six donors differed in their capacity
to elicit an IE-1- and/or pp65-dependent response in the
IFN-γ ELISpot assay. The intensity of the response was
also heterogeneous among the six donors, with values ran-
ging from 7 to 1,054 SFC (IE-1 stimulation) and from 28
to 780 SFC (pp65 stimulation) per 200,000 PBMC (Fig. 9a).
Similarly, individual donors differed in the frequency and
ratio of the various cell subpopulations investigated by
flow cytometry (Fig. 9b). Interestingly, healthy CMV-
seropositive individuals with lower spot counts (d120,
d300, d343; Fig. 9a) also showed lower frequencies of IFN-
γ+ lymphocytes by flow cytometry (Fig. 9b), highlighting
the ability of the ELISpot assay to distinguish low from
high responders. Activation of each lymphocyte subpopu-
lation investigated was detected in some but not all
donors. For instance, weak to strong CD4+ T cell activa-
tion was detected in 4 out of 6 donors (d120, d172, d300,
d343) in response to either IE-1, pp65, or both. Similarly,
5 out of 6 donors (d172, d290, d300, d343, d361) showed
CD8+ T cell activation in one or both stimulation condi-
tions. CD3-CD56+ (NK cells) were apparent in one donor
(d120) in response to both antigens. CD3+CD56+ (NKT-
like) cells were weakly activated in 4 out of 6 individuals
(d120, d172 d300, d361) in response to both IE-1 and
pp65 (Fig. 9b). Remarkably, a strong pp65-specific CD4+
activation in d172 correlated with a strong pp65-specific
response in ELISpot, and a strong pp65-specific (d290)
and IE-1-specific (d361) CD8+ activation was associated
with a high spot count in the corresponding ELISpot
(Figs. 9a-b), suggesting that these CMV-reactive effector
cells significantly contribute to the detected ELISpot sig-
nals. Altogether, these data demonstrate the ability of
T-activated® IE-1 and pp65 proteins to stimulate a broad
range of CMV-specific effector cells. These experiments
also revealed the high heterogeneity of responses among
healthy CMV-seropositive individuals. Notably, the obser-
vation that some individuals respond to either IE-1 or
pp65 emphasizes the importance of assessing the response
to both antigens. Monitoring both IE-1- and pp65-specific
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responses in the optimized IFN-γ ELISpot assay might im-
prove the overall sensitivity of the test.
Discussion
We describe here the development and technical valid-
ation of an optimized and standardized IFN-γ ELISpot
protocol for the monitoring of CMV-reactive effector
cells of cell-mediated immunity (CMI).
The particularity of the assay is the use of T-
activated® proteins [31] as stimulant of CMV-reactive
effector cells. We now demonstrate that urea-
formulated IE-1 and pp65 proteins are capable of ac-
tivating not only CMV-reactive CD4+ (Th) and CD8+
(CTL) lymphocytes, but also innate lymphocytes (CD3
−CD56+ NK and CD3+CD56+ NKT-like cells), likely
by bystander activation as well as by activation of
CMV-specific memory NK cells [5, 7, 8, 32, 50, 51].
This finding is important given the acknowledged role
played by these effector cells in the protection against
CMV reactivation in vivo [5–12]. Inter-individual vari-
ability in the response of lymphocyte subpopulations
was high among CMV-seropositive healthy donors,
therefore further emphasizing the importance of an
antigen formulation capable of activating a broad
spectrum of CMV-reactive effector cells. In this, the
optimized IFN-γ ELISpot assays outperforms existing
ELISpot- and ELISA-based CMV-specific CMI moni-
toring tools. In addition, the characteristics and high
sensitivity of our assay predict a performance inde-
pendent of the HLA-type of the donor.
Fig. 9 T-activated® pp65 and IE-1 CMV antigens stimulate a broad range of CMV-reactive effector cells. Comparative analysis of IFN-γ secreting
cells by ELISpot (a) and flow cytometry (b) following stimulation of PBMC with T-activated® pp65 and IE-1 antigens. PBMC (4 replicates each) from
six CMV-seropositive healthy donors (median age and range of 39 (22–55) years; 2 male and 4 female) were stimulated with T-activated® pp65
and IE-1 antigens according to the optimized IFN-γ ELISpot (a) and to the protocol of intracellular and surface marker staining and flow cytometry
described in the Methods section (b). Bar graphs in (a) depict IFN-γ-dependent SFC per 200,000 PBMC, as before. Bar graphs in (b) represent the
number of IFN-γ-expressing CD3+CD4+ (Th), CD3+CD8+ (CTL), CD3−CD56+ (NK) and CD3+CD56+ (NKT-like) cells per 200,000 lymphocytes. Note
that the Y-axis scales in (b) were adjusted for a better resolution of the respective data. Individual age and gender of donors were as follows:
d120, 37-year-old male; d172, 55-year-old female; d290, 46-year-old female; d300, 41-year-old female; d343, 24-year-old female; d361, 22-year-old male
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The second particularity of the described assay is the
combined use of two T-activated® proteins, IE-1 and
pp65, as antigens. We show here that both antigens can
elicit the activation of distinct CMV-specific effector
cells and that while some CMV-seropositive healthy in-
dividuals are reactive to both antigens, some are only re-
active to one (either IE-1 or pp65), as previously
reported [52]. Therefore, consideration of both test re-
sults is expected to improve the sensitivity of the assay,
notably in cohort studies. This is particularly relevant
for the monitoring of CMV-specific CMI in immuno-
compromized patients. Accordingly, we recently demon-
strated the benefit of measuring the response to both
T-activated® IE-1 and pp65 antigens in terms of assay
sensitivity, in clinical studies assessing CMV-specific
CMI during pregnancy [53], in hemodialysis patients
[49] and in renal transplant recipients (submitted).
The assessment of the response to both IE-1 and pp65
antigens is further justified by the respective relevance
and differential contribution of IE-1- and pp65-reactive
effector cells to the protection against CMV reactivation
and related clinical complications, both in healthy
CMV-seropositive individuals and in transplant recipi-
ents [1, 6, 54–59]. The differential contribution of IE-1-
and pp65-specific effector cells likely reflect the dynamic
of the cell-mediated immune response [10, 60–64].
Mechanisms of immune evasion inhibiting MHC-I-
dependent IE-1 antigen processing and presentation
might also explain the lower frequency of IE-1-specific
IFN-γ-producing cells detected in our ELISpot assay
[65]. In addition, reduced processing and presentation
efficiency due to protein stability, size and nuclear
localization might play a role in the reduced reactivity to
IE-1, as opposed to pp65 [64, 66, 67]. This proposition is
supported by the observation that higher concentrations
of IE-1 were required in our ELISpot assay, in compari-
son to pp65, to trigger a significant response.
Another particularity of our IFN-γ ELISpot assay was
its ability to elicit positive test results in CMV-
seronegative individuals, notably following stimulation
with IE-1. In the cohort of 45 healthy donors, out of the
13 CMV-seronegative individuals 2 showed IE-1-specific
values ≥ 10 SFC/200,000 PBMC (Additional File 2),
corresponding to a negative agreement with CMV IgG-
serology of 85%. Similar results were obtained in a
cohort of 124 hemodialysis patients [49]. Numerous
studies reported discordant results between cellular and
humoral immunity against CMV [68–71]. Given the
high sensitivity of our ELISpot assay and its ability to de-
tect a broad range of CMV-reactive cells, it is possible
that cellular reactivity in CMV-seronegative individuals
reflects a previous exposure to CMV that failed to
mount a humoral immune response, rather than a
false-positive ELISpot result. Further experiments will
be necessary to address this possibility. Nonetheless, this
observation raises the question of the accuracy of CMV
serology to identify immunocompromised patients at
increased risk of CMV reactivation [3, 70, 72].
The optimized and standardized IFN-γ ELISpot assay
exhibited robust performance in terms of assay variabil-
ity, precision and linearity. Intra-assay, inter-assay and
inter-operator coefficients of variations (CV) did not ex-
ceed 22%, which is below the range of recommended
precision (% of relative standard deviation or %RSD) for
cell-based assays [73]. As predicted, inter-site variability
involving different operators was higher, but remained
acceptable with a CV of no more than 39%. This is an
important criterion for the reliable longitudinal monitor-
ing of CMV-specific immune responses in patients.
Linearity of the assay is also a critical parameter, in par-
ticular for the monitoring of immunocompromized pa-
tients with reduced and/or functionally impaired T cells,
such as children or recipients of allogeneic stem cell
transplantation. Good linearity and high signal-to-noise
ratio were obtained for both IE-1 (R2 = 0.97) and pp65
(R2 = 0.99) in the range of 60,000 to 200,000 PBMC per
well. Two multi-center clinical studies are currently be-
ing conducted, in renal transplant recipients under im-
munosuppressive therapy and in allogeneic stem cell
transplantation patients, to assess the sensitivity of the
optimized CMV-specific IFN-γ ELISpot assay in this
clinical context and to correlate results of the assay to
clinical outcome.
Conclusions
Altogether, this optimized, standardized and user-
friendly CMV-specific IFN-γ ELISpot assay meet all the
conditions of a sensitive and reliable diagnostic test for
the monitoring of the functionality of CMV-specific
CMI. Beside its validation in healthy individuals (this
study), its suitability to assess CMV-specific cell-
mediated immunity in a cohort of hemodialysis patients
representative of patients prior to transplantation has
been demonstrated [49]. Further validation of the assay
in immunocompromised patients, such as transplant re-
cipients is necessary to determine its suitability in assist-
ing clinicians to evaluate the risk of CMV reactivation
and disease, and possibly individualize the therapeutic
management of patients.
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Additional files
Additional File 1: Assay variability. Intra-assay (Table
S1.), inter-assay (Table S2.), inter-operator (Table S3.)
and inter-site (Table S4.) variability was assessed as de-
scribed in the respective legends. (PDF 128 kb)Addi-
tional File 2: Positivity cut-off definition. Results
obtained using the optimized IFN-γ ELISpot assay on
PBMC isolated from whole blood of 45 healthy donors
(Table 1 and Fig. 8) were used to generate precision pro-
files for each IE-1 and pp65 stimulation. Limits of quanti-
tation (LoQ) for IE-1 and pp65 were 8.6 and 7.1 SFC/
200,000 PBMC respectively. LoQ calculated on a cohort
of 124 hemodialysis patients [49] were in a similar range
(7.8 and 8.3 for IE-1 and pp65 respectively). Therefore, a
positivity cut-off of 10 SFC/200,000 PBMC was chosen for
the standardized assay. In addition, intra-assay standard
deviation (SD) within both cohorts of healthy donors (n =
45) and hemodialysis patients (n = 124) for stimulated
and unstimulated measurements was the basis for the cal-
culation of a criterion that the ratio of geometric means of
stimulated to unstimulated values is at least 2.5. Finally,
considering a test result as positive when geometric mean
for at least one of the IE-1 or pp65 stimulated approach is ≥
10 SFC/200,000 PBMC, positive agreement (sensitivity)
and negative agreement (specificity) of the optimized
IFN-γ ELISpot test results with CMV serology within
the collective of 45 healthy donors was 97% and 85%
respectively (Fig. 8). (PDF 73 kb)Additional File 3:
Gating strategy of flow cytometry analyses following
surface marker (CD3, CD4, CD8, CD56) and intracel-
lular IFN-γ staining. PBMC (4 replicates each) from
six CMV-seropositive healthy donors were stimulated
with T-activated® pp65 and IE-1 antigens for 6 h, as
indicated in the legend to Fig. 9. (A) Cells were first
gated on single events in a Forward Scatter-Area
(FSC-A) x FSC-Height (FSC-H) dot plot (Gating #1).
Based on FSC-A x Side Scatter-Area (SSC-A) proper-
ties, a gate was next set around lymphocytes (Gating
#2). By plotting CD3 against CD56, CD56 single posi-
tive cells (Gating #3), CD3/CD56 double positive cells
(Gating #4) and CD3 single positive cells (Gating #5)
were separated. CD3 single positive cells (Gating #5)
were further subdivided into CD3/CD4 double posi-
tive (Gating #6) and CD3/CD8 double positive cells
(Gating #7). (B) Representative dot plots (1 out of 4
replicates) of stained PBMC of donor d290. In each
plot, percentage value in gated area is the mean fre-
quency (from 4 replicates) of IFN-γ-expressing CD3
+CD4+ (Th), CD3+CD8+ (CTL), CD3−CD56+ (NK)
and CD3+CD56+ (NKT-like) cells. (PDF 351 kb)
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